Impact of age, sex, and comorbidity on cancer therapy and disease progression

Journal of Clinical Oncology

Volumn 28, Issue 26, 2010, Pages 4086-4093

  Pal, Sumanta Kumar ^a   Hurria, Arti ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; TEMOZOLOMIDE;

AGE DISTRIBUTION; AGING; ANEMIA; BONE MARROW; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CANCER THERAPY; COGNITION; COLON CANCER; COMORBIDITY; DECISION MAKING; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG CLEARANCE; FUNCTIONAL STATUS; GENE MUTATION; GERIATRIC ASSESSMENT; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; NEOPLASM; NEUTROPENIA; NUTRITIONAL STATUS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SENESCENCE; SEX DIFFERENCE; SOCIAL INTERACTION; SOCIAL STATUS; SOCIAL SUPPORT; THROMBOCYTOPENIA; AGE; DISEASE COURSE; FEMALE; MALE; MORTALITY; PHYSIOLOGY;

AGE FACTORS; AGING; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEOPLASMS; PROGNOSIS; SEX FACTORS;

EID: 77956938954     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.0579     Document Type: Review

References (126)

1. Schilsky RL: Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol 27:3725-3730, 2009
2. Hutchins L, Unger J, Crowley J, et al: Under-representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067, 1999 (Pubitemid 30035956)
3. Ries LAG, Melbert D, Krapcho M, et al: SEER cancerstatisticsreview,1975- 2005.http://seer.cancer.gov/statfacts/html/all.html
4. Piccirillo JF, Tierney RM, Costas I, et al: Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 291:2441-2447, 2004 (Pubitemid 38669187)
5. Wakelee HA, Wang W, Schiller JH, et al: Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 1:441-446, 2006 (Pubitemid 47181421)
6. Giacchetti S, Bjarnason G, Garufi C, et al: Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24:3562-3569, 2006 (Pubitemid 46630527)
7. Smith BD, Smith GL, Hurria A, et al: Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 27:2758-2765, 2009
8. Kaiser JC, Heidenreich WF, Monchaux G, et al: Lung tumour risk in radon-exposed rats from different experiments: Comparative analysis with biologically based models. Radiat Environ Biophys 43:189-201, 2004 (Pubitemid 39592784)
9. Slebos RJC, Li M, Vadivelu S, et al: Microsatellite mutations in buccal cells are associated with aging and head and neck carcinoma. Br J Cancer 98:619-626, 2008 (Pubitemid 351214527)
10. Campisi J, Kim S-h, Lim C-S, et al: Cellular senescence, cancer and aging: The telomere connection. Exp Gerontol 36:1619-1637, 2001 (Pubitemid 32982869)
11. Lustgarten J: Cancer, aging and immunotherapy: Lessons learned from animal models. Cancer Immunol Immunother 58:1979-1989, 2009
12. Song YS, Lee BY, Hwang ES: Dinstinct ROS and biochemical profiles in cells undergoing DNA damage-induced senescence and apoptosis. Mech Ageing Dev 126:580-590, 2005 (Pubitemid 40461957)
13. Jemal A, Center MM, Ward E, et al: Cancer occurrence, in Verma M (ed): Cancer Epidemiology (vol 1). New York, NY, Humana Press, 2009, pp 3-29
14. Kanapuru B, Posani K, Muller D, et al: Decreased cancer prevalence in the nursing home. J Am Geriatr Soc 56:2165-2166, 2008
15. Stanta G, Campagner L, Cavallieri F, et al: Cancer of the oldest old: What we have learned from autopsy studies. Clin Geriatr Med 13:55-68, 1997 (Pubitemid 27084043)
16. Appelbaum FR, Gundacker H, Head DR, et al: Age and acute myeloid leukemia. Blood 107:3481-3485, 2006
17. Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92:550-556, 2000 (Pubitemid 30212316)
18. Kantarjian H, O'Brien S, Cortes J, et al: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 106:1090-1098, 2006
19. Lowenberg B, Ossenkoppele GJ, van Putten W, et al: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361:1235-1248, 2009
20. Vestal RE: Aging and pharmacology. Cancer 80:1302-1310, 1997
21. Go RS, Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17:409-422, 1999 (Pubitemid 29022420)
22. Toffoli G, Corona G, Sorio R, et al: Population pharmacokinetics and pharmacodynamics of oral etoposide. Br J Clin Pharmacol 52:511-519, 2001
23. Bressolle F, Bologna C, Kinowski JM, et al: Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis 57:110-113, 1998 (Pubitemid 28177541)
24. Baker SD, Grochow LB: Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 13:169-183, 1997
25. Yuen GJ: Altered pharmacokinetics in the elderly. Clin Geriatr Med 6:257-267, 1990
26. Sotaniemi EA, Arranto AJ, Pelkonen O, et al: Age and cytochrome P450-linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 61:331-339, 1997 (Pubitemid 27145435)
27. Sawhney R, Sehl M, Naeim A: Physiologic aspects of aging: Impact on cancer management and decision making, part I. Cancer J 11:449-460, 2005 (Pubitemid 43097072)
28. NCCN Practice Guidelines in Oncology (v. 1.2009): Myeloid growth factors. http://www.nccn.org/professionals/physician-gls/PDF/myeloid-growth.pdf
29. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006
30. Milano G, Etienne M, Cassuto-Viguier E, et al: Influence of sex and age on fluorouracil clearance. J Clin Oncol 10:1171-1175, 1992
31. Cassidy J, Twelves C, Cameron D, et al: Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 44:453-460, 1999 (Pubitemid 29501014)
32. Slaviero KA, Clarke SJ, McLachlan AJ, et al: Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 57:44-53, 2004 (Pubitemid 38067949)
33. ten Tije AJ, Verweij J, Carducci MA, et al: Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 23:1070-1077, 2005
34. Li J, Gwilt PR: The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol 51:395-402, 2003 (Pubitemid 36649136)
35. Ando M, Minami H, Ando Y, et al: Pharmacological analysis of etoposide in elderly patients with lung cancer. Clin Cancer Res 5:1690-1695, 1999 (Pubitemid 29334447)
36. Graham MA, Lockwood GF, Greenslade D, et al: Clinical pharmacokinetics of oxaliplatin: A critical review. Clin Cancer Res 6:1205-1218, 2000 (Pubitemid 30226200)
37. Lichtman S, Hollis D, Miller A, et al: Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 24:1846-1851, 2006
38. Fidias P, Supko JG, Martins R, et al: A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res 7:3942-3949, 2001 (Pubitemid 34044612)
39. Jen JF, Cutler DL, Pai SM, et al: Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 17:1284-1289, 2000
40. Gauvin A, Pinguet F, Culine S, et al: Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 6:2690-2695, 2000 (Pubitemid 30482105)
41. Sorio R, Robieux I, Galligioni E, et al: Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 33:301-303, 1997
42. Bajetta E, Procopio G, Celio L, et al: Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 23:2155-2161, 2005 (Pubitemid 46218707)
43. Klepin H, Mohile S, Hurria A: Geriatric assessment in older patients with breast cancer. J Natl Compr Canc Netw 7:226-236, 2009
44. Maione P, Perrone F, Gallo C, et al: Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: A prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23:6865-6872, 2005
45. Wedding U, Röhrig B, Klippstein A, et al: Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol 133:945-950, 2007 (Pubitemid 47561710)
46. Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104-110, 1994 (Pubitemid 24027550)
47. Gupta SK, Lamont EB: Patterns of presentation, diagnosis, and treatment in older patients with colon cancer and comorbid dementia. Journal of the American Geriatrics Society 52:1681-1687, 2004 (Pubitemid 41709922)
48. Heck JE, Albert SM, Franco R, et al: Patterns of dementia diagnosis in surveillance, epidemiology, and end results breast cancer survivors who use chemotherapy. J Am Geriatr Soc 56:1687-1692, 2008
49. Hurria A, Li D, Hansen K, et al: Distress in older patients with cancer. J Clin Oncol 27:4346-4351, 2009
50. Kroenke CH, Kubzansky LD, Schernhammer ES, et al: Social networks, social support, and survival after breast cancer diagnosis. J Clin Oncol 24:1105-1111, 2006 (Pubitemid 46646222)
51. Bried EM, Scheffler RM: The financial stages of cancer in the elderly. Oncology (Williston Park) 6:153-160, 1992
52. Sokol KC, Knudsen JF, Li MM: Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 32:169-175, 2007 (Pubitemid 46449710)
53. Andreyev HJN, Norman AR, Oates J, et al: Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34:503-509, 1998
54. Buccheri G, Ferrigno D: Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer. Lung Cancer 34:433-440, 2001 (Pubitemid 33041479)
55. Cohen HJ, Muss HB: The Cancer and Leukemia Group B Cancer in the Elderly Committee: Addressing a major cancer need. Clin Cancer Res 12:3606s-3611s, 2006
56. Fried LP, Tangen CM, Walston J, et al: Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146-157, 2001
57. Bandeen-Roche K, Xue Q-L, Ferrucci L, et al: Phenotype of frailty: Characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci 61:262-266, 2006
58. Xue Q-L, Bandeen-Roche K, Varadhan R, et al: Initial manifestations of frailty criteria and the development of frailty phenotype in the Women's Health and Aging Study II. J Gerontol A Biol Sci Med Sci 63:984-990, 2008
59. Yancik R: Cancer burden in the aged: An epidemiologic and demographic overview. Cancer 80:1273-1283, 1997
60. Konety BR, Cowan JE, Carroll PR: Patterns of primary and secondary therapy for prostate cancer in elderly men: Analysis of data from CaPSURE. J Urol 179:1797-1803, 2008
61. Smith TJ, Penberthy L, Desch CE, et al: Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer 13:235-252, 1995 (Pubitemid 26022990)
62. Yancik R, Wesley MN, Ries LAG, et al: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885-892, 2001 (Pubitemid 32171549)
63. Keating NL, Landrum MB, Klabunde CN, et al: Adjuvant chemotherapy for stage III colon cancer: Do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 26:2532-2537, 2008
64. Hurria A, Wong FL, Villaluna D, et al: Role of age and health in treatment recommendations for older adults with breast cancer: The perspective of oncologists and primary care providers. J Clin Oncol 26:5386-5392, 2008
65. Blanco JAG, Toste IS, Alvarez RF, et al: Age, comorbidity, treatment decision and prognosis in lung cancer. Age Ageing 37:715-718, 2008
66. Aparicio T, Desrame J, Lecomte T, et al: Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 89:1439-1444
67. Asmis TR, Ding K, Seymour L, et al: Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: A review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26:54-59, 2008
68. Moscetti L, Nelli F, Padalino D, et al: Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: Impact of comorbidities on safety and efficacy outcome. J Chemother 17:685-692, 2005 (Pubitemid 43097759)
69. Nanda A, Chen M-H, Braccioforte MH, et al: Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302:866-873, 2009
70. Meyerhardt JA, Catalano PJ, Haller DG, et al: Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 21:433-440, 2003 (Pubitemid 46606471)
71. Payne JE, Meyer HJ: The influence of other diseases upon the outcome of colorectal cancer patients. Aust N Z J Surg 65:398-402, 1995
72. Yancik R, Wesley MN, Ries LAG, et al: Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients. Cancer 82:2123-2134, 1998 (Pubitemid 28240818)
73. Tran TT, Medline A, Bruce WR: Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 5:1013-1015, 1996 (Pubitemid 26415875)
74. Wolpin BM, Meyerhardt JA, Chan AT, et al: Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27:176-185, 2009
75. Goodwin PJ, Ennis M, Pritchard KI, et al: Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 20:42-51, 2002 (Pubitemid 34032594)
76. Jiralerspong S, Palla SL, Giordano SH, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302, 2009
77. Goodwin PJ, Ligibel JA, Stambolic V: Metformin in breast cancer: Time for action. J Clin Oncol 27:3271-3273, 2009
78. Frasci G, Lorusso V, Panza N, et al: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18:2529-2536, 2000 (Pubitemid 30432518)
79. Zauderer M, Patil S, Hurria A: Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer. Breast Cancer Res Treat 117:205-210, 2008
80. Rowinsky EK, Eisenhauer EA, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1-15, 1993 (Pubitemid 23239390)
81. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
82. Suter TM, Procter M, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859-3865, 2007 (Pubitemid 47477261)
83. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
84. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
85. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
86. Dahlberg SE, Sandler AB, Brahmer JR, et al: Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599. J Clin Oncol 27:417s, 2009 (abstr 8042)
87. Schneider BP, Wang M, Radovich M, et al: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678, 2008
88. Jain RK, Duda DG, Sorensen AG: Emerging Paradigms and Potential Biomarkers of Response and Resistance in Antiangiogenic Therapy of Cancer. Alexandria, VA, American Society of Clinical Oncology, 2009, pp 716-721
89. Ferguson M, Skosey C, Hoffman P, et al: Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 8:1402-1407, 1990 (Pubitemid 20252313)
90. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006 (Pubitemid 44343542)
91. Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291, 2002 (Pubitemid 34753602)
92. Ceppi P, Volante M, Novello S, et al: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17:1818-1825, 2006
93. Holm B, Mellemgaard A, Skov T, et al: Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 27:4254-4259, 2009
94. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
95. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
96. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004 (Pubitemid 39209661)
97. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005 (Pubitemid 40812628)
98. Han S-W, Kim T-Y, Hwang PG, et al: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-2501, 2005 (Pubitemid 47050839)
99. Tam IY, Chung LP, Suen WS, et al: Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12:1647-1653, 2006
100. Singh S, Parulekar W, Murray N, et al: Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol 23:850-856, 2005 (Pubitemid 46224185)
101. Schwab M, Zanger UM, Marx C, et al: Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26:2131-2138, 2008
102. Sloan JA, Goldberg RM, Sargent DJ, et al: Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20:1491-1498, 2002 (Pubitemid 34260527)
103. Milano G, Etienne MC, Pierrefite V, et al: Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79:627-630, 1999 (Pubitemid 29046246)
104. Benet LZ, Cummins CL, Wu CY: Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277:3-9, 2004 (Pubitemid 38670415)
105. Schuetz E, Furuya K, Schuetz J: Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275:1011-1018, 1995 (Pubitemid 26023635)
106. Asperen Jv, Tellingen Ov, Tijssen F, et al: Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 79:108-113, 1998 (Pubitemid 28566934)
107. Cummins CL, Wu C-Y, Benet LZ: Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 72:474-489, 2002 (Pubitemid 36237718)
108. Ishibashi H, Suzuki T, Suzuki S, et al: Progesterone receptor in non-small cell lung cancer: A potent prognostic factor and possible target for endocrine therapy. Cancer Res 65:6450-6458, 2005 (Pubitemid 40994434)
109. Nose N, Sugio K, Oyama T, et al: Association between estrogen receptor-{beta} expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 27:411-417, 2009
110. Charlson M, Szatrowski TP, Peterson J, et al: Validation of a combined comorbidity index. J Clin Epidemiol 47:1245-1251, 1994 (Pubitemid 24361532)
111. Inouye SK, Peduzzi PN, Robison JT, et al: Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 279:1187-1193, 1998
112. Lee SJ, Lindquist K, Segal MR, et al: Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 295:801-808, 2006 (Pubitemid 43244307)
113. Walter LC, Brand RJ, Counsell SR, et al: Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA 285:2987-2994, 2001 (Pubitemid 32550117)
114. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987 (Pubitemid 17055592)
115. Gross CP, Guo Z, McAvay GJ, et al: Multimorbidity and survival in older persons with colorectal cancer. J Am Geriatr Soc 54:1898-1904, 2006
116. Wang R, Gross CP, Halene S, et al: Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 33:1594-1598, 2009
117. de Cos JS, Miravet L, Abal J, et al: Lung cancer survival in Spain and prognostic factors: A prospective, multiregional study. Lung Cancer 59:246-254, 2008 (Pubitemid 351181342)
118. Maas HA, Kruitwagen RF, Lemmens VE, et al: The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: A population-based study. Gynecol Oncol 97:104-109, 2005 (Pubitemid 40403681)
119. Nguyen PL, Chen M-H, Beard CJ, et al: Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer 116:610-615, 2010
120. Kim WY, Sharpless NE: The regulation of INK4/ARF in cancer and aging. Cell 127:265-275, 2006 (Pubitemid 44572384)
121. Wiencke JK, Zheng S, Lafuente A, et al: Aberrant methylation of p16INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev 8:501-506, 1999 (Pubitemid 29270333)
122. Li X, Hui A, Sun L, et al: P16INK4A hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. Clin Cancer Res 10:7484-7489, 2004 (Pubitemid 39557509)
123. Firoz EF, Warycha M, Zakrzewski J, et al: Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clin Cancer Res 15:2573-2580, 2009
124. Yancik R, Ershler W, Satariano W, et al: Report of the National Institute on Aging Task Force on Comorbidity. J Gerontol A Biol Sci Med Sci 62:275-280, 2007 (Pubitemid 47065724)
125. Balducci L, Tam-McDevitt J, Hauser R, et al: Long overdue: Phase II Studies in Older Cancer Patients: Where Does the FDA Stand? J Clin Oncol 26:1387-1388, 2008
126. Kornblith AB, Kemeny M, Peterson BL, et al: Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 95:989-996, 2002 (Pubitemid 34925347)